Hurst Melanie N, Beebout Connor J, Hollingsworth Alexis, Guckes Kirsten R, Purcell Alexandria, Bermudez Tomas A, Williams Diamond, Reasoner Seth A, Trent M Stephen, Hadjifrangiskou Maria
Division of Molecular Pathogenesis, Department of Pathology, Microbiology & Immunology, Vanderbilt University Medical Center, Nashville, TN, USA.
Department of Biological Sciences, Vanderbilt University, Nashville, TN, USA.
bioRxiv. 2023 Jan 11:2023.01.10.523522. doi: 10.1101/2023.01.10.523522.
The modification of lipopolysaccharide (LPS) in and . is primarily controlled by the two-component system PmrAB. LPS modification allows bacteria to avoid killing by positively charged antibiotics like polymyxin B. We previously demonstrated that in uropathogenic (UPEC), the sensor histidine kinase PmrB also activates a non-cognate transcription factor, QseB, and this activation somehow augments polymyxin B tolerance in UPEC. Here, we demonstrate - for the first time - that in the absence of the canonical LPS transcriptional regulator, PmrA, QseB can direct some modifications on the LPS. In agreement with this observation, transcriptional profiling analyses demonstrate regulatory overlaps between PmrA and QseB in terms of regulating LPS modification genes. However, both PmrA and QseB must be present for UPEC to mount robust tolerance to polymyxin B. Transcriptional and metabolomic analyses also reveal that QseB transcriptionally regulates the metabolism of glutamate and 2-oxoglutarate, which are consumed and produced during the modification of lipid A. We show that deletion of alters glutamate levels in the bacterial cells. The deletion mutant, which is susceptible to positively charged antibiotics, is rescued by exogenous addition of 2-oxoglutarate. These findings uncover a previously unknown mechanism of metabolic control of antibiotic tolerance that may be contributing to antibiotic treatment failure in the clinic.
Although antibiotic prescriptions are guided by well-established susceptibility testing methods, antibiotic treatments oftentimes fail. The presented work is significant, because it uncovers a mechanism by which bacteria transiently avoid killing by antibiotics. This mechanism involves two closely related transcription factors, PmrA and QseB, which are conserved across Enterobacteriaceae. We demonstrate that PmrA and QseB share regulatory targets in lipid A modification pathway and prove that QseB can orchestrate modifications of lipid A in in the absence of PmrA. Finally, we show that QseB controls glutamate metabolism during the antibiotic response. These results suggest that rewiring of QseB-mediated metabolic genes can lead to stable antibiotic resistance in subpopulations within the host, thereby contributing to antibiotic treatment failure.
在[具体细菌名称1]和[具体细菌名称2]中,脂多糖(LPS)的修饰主要由双组分系统PmrAB控制。LPS修饰使细菌能够避免被带正电荷的抗生素(如多粘菌素B)杀死。我们之前证明,在尿路致病性大肠杆菌(UPEC)中,传感器组氨酸激酶PmrB还会激活一个非同源转录因子QseB,并且这种激活以某种方式增强了UPEC对多粘菌素B的耐受性。在此,我们首次证明,在缺乏典型LPS转录调节因子PmrA的情况下,QseB可以指导LPS上的一些修饰。与这一观察结果一致,转录谱分析表明,在调节LPS修饰基因方面,PmrA和QseB之间存在调控重叠。然而,UPEC要对多粘菌素B产生强大的耐受性,PmrA和QseB必须同时存在。转录组和代谢组分析还表明,QseB在转录水平上调节谷氨酸和2-氧代戊二酸的代谢,这两种物质在脂质A修饰过程中被消耗和产生。我们发现缺失[相关基因名称]会改变细菌细胞中的谷氨酸水平。对带正电荷抗生素敏感的[相关基因名称]缺失突变体,通过外源添加2-氧代戊二酸得以挽救。这些发现揭示了一种以前未知的抗生素耐受性代谢控制机制,这可能是导致临床抗生素治疗失败的原因。
尽管抗生素处方是由成熟的药敏试验方法指导的,但抗生素治疗常常失败。本文的工作意义重大,因为它揭示了细菌暂时避免被抗生素杀死的一种机制。这种机制涉及两个密切相关的转录因子PmrA和QseB,它们在肠杆菌科中是保守的。我们证明PmrA和QseB在脂质A修饰途径中共享调控靶点,并证明在没有PmrA的情况下,QseB可以协调[具体细菌名称]中脂质A的修饰。最后,我们表明QseB在抗生素应答过程中控制谷氨酸代谢。这些结果表明,QseB介导的代谢基因的重新布线可导致宿主内亚群产生稳定的抗生素抗性,从而导致抗生素治疗失败。